Teleflex Incorporated, a provider of medical devices for critical care and surgery, has received FDA 510-k clearance for central venous pressure, or CVP, monitoring indication for its ArrowADVANTAGE5 pressure-injectable peripherally inserted central catheter, or PICC.
The change in CVP, correlated with the patient's clinical status, is a useful indication of adequacy of venous blood volume and alterations in cardiovascular function. CVP also reflects the pumping ability of the right atrium and ventricle.
"With the ArrowADVANTAGE5, we offer the next generation of non-coated pressure-injectable PICCs," commented Paul Molloy, president, Vascular Division of Teleflex. "Beyond the unique advantages of our PICC, we are pleased to add the CVP monitoring indication. Additionally, the distal lumen is compatible with the ARROW VPS System, enabling clinicians to combine the advantages of our PICC with state-of-the-art tip location technology."